NeoImmuneTech takes over Endari’s U.S. rights from Emmaus: What this signals for the future of sickle cell treatment
NeoImmuneTech takes over U.S. rights for Endari from Emmaus Life Sciences. Find out what this deal reveals about the future of sickle cell treatment.